HP
HealthInvest Partners Portfolio holdings
AUM $234M
1-Year Return
10.88%
This Quarter Return
+1.01%
1 Year Return
+10.88%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$164M
AUM Growth
-$349K
(-0.21%)
Cap. Flow
+$3.28M
Cap. Flow
% of AUM
2%
Top 10 Holdings %
Top 10 Hldgs %
67.19%
Holding
47
New
3
Increased
23
Reduced
11
Closed
9
Top Buys
| 1 |
Eli Lilly
LLY
|
+$5.76M |
| 2 |
UnitedHealth
UNH
|
+$4.4M |
| 3 |
Amgen
AMGN
|
+$2.72M |
| 4 |
UFP Technologies
UFPT
|
+$2.59M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$2.36M |
Top Sells
| 1 |
Harmony Biosciences
HRMY
|
+$4.08M |
| 2 |
Elevance Health
ELV
|
+$3.84M |
| 3 |
Gilead Sciences
GILD
|
+$3.81M |
| 4 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$2.96M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$2.73M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$671B
| $24.6M | 14.98% |
27,144
+6,366
| +31% | +$5.76M |
|
|
2
UnitedHealth
UNH
$315B
| $16.1M | 9.84% |
31,680
+8,639
| +37% | +$4.4M |
|
3
Merck
MRK
$202B
| $14M | 8.51% |
112,734
-21,007
| -16% | -$2.6M |
|
|
4
Thermo Fisher Scientific
TMO
$179B
| $10.8M | 6.56% |
19,458
+4,272
| +28% | +$2.36M |
|
|
5
Amgen
AMGN
$148B
| $8.62M | 5.26% |
27,589
+8,698
| +46% | +$2.72M |
|
6
Boston Scientific
BSX
$148B
| $8.21M | 5% |
106,557
+29,156
| +38% | +$2.25M |
|
7
Regeneron Pharmaceuticals
REGN
$60.7B
| $7.24M | 4.42% |
6,893
+1,500
| +28% | +$1.58M |
|
8
Vertex Pharmaceuticals
VRTX
$101B
| $7.08M | 4.31% |
15,095
+3,800
| +34% | +$1.78M |
|
9
Cencora
COR
$56.5B
| $6.83M | 4.17% |
30,320
+9,894
| +48% | +$2.23M |
|
10
Stryker
SYK
$144B
| $6.8M | 4.15% |
19,983
+4,829
| +32% | +$1.64M |
|
11
AbbVie
ABBV
$384B
| $6.11M | 3.73% |
35,618
+6,272
| +21% | +$1.08M |
|
12
DexCom
DXCM
$29.6B
| $3.91M | 2.38% |
34,483
+8,200
| +31% | +$930K |
|
13
Edwards Lifesciences
EW
$44.6B
| $3.37M | 2.06% |
36,505
+11,730
| +47% | +$1.08M |
|
|
14
Neurocrine Biosciences
NBIX
$13.9B
| $3.25M | 1.98% |
23,630
-19,850
| -46% | -$2.73M |
|
15
IQVIA
IQV
$31.6B
| $2.96M | 1.8% |
13,984
+3,926
| +39% | +$830K |
|
16
Molina Healthcare
MOH
$9.55B
| $2.82M | 1.72% |
9,500
-2,500
| -21% | -$743K |
|
17
Cardinal Health
CAH
$35.9B
| $2.7M | 1.65% |
27,500
| – | – |
|
|
18
UFP Technologies
UFPT
$1.57B
| $2.59M | 1.58% |
+9,800
| New | +$2.59M |
|
19
Mirum Pharmaceuticals
MIRM
$3.73B
| $2.57M | 1.57% |
75,200
-47,800
| -39% | -$1.63M |
|
|
ITCI
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.45M | 1.5% |
35,841
-2,209
| -6% | -$151K |
|
21
Ionis Pharmaceuticals
IONS
$9.74B
| $1.94M | 1.18% |
40,691
-23,100
| -36% | -$1.1M |
|
22
Merus
MRUS
$5.15B
| $1.82M | 1.11% |
30,837
+6,512
| +27% | +$385K |
|
23
Corbus Pharmaceuticals
CRBP
$115M
| $1.77M | 1.08% |
39,100
+1,100
| +3% | +$49.8K |
|
24
Alkermes
ALKS
$4.38B
| $1.66M | 1.01% |
+68,800
| New | +$1.66M |
|
25
Option Care Health
OPCH
$4.53B
| $1.51M | 0.92% |
54,395
-78,500
| -59% | -$2.17M |
|